Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
—
—
—
Bliss GVS Pharma Limited is engaged in developing, manufacturing and marketing pharmaceutical formulations.
Customise key metrics, see detailed forecasts, download stock data and more
Pledged promoter holdings is insignificant
In last 3 months, mutual fund holding of the company has almost stayed constant
Bliss GVS Pharma Limited has informed the Exchange regarding 'We like to inform you that, the ESOP Allotment Committee of the Company at its meeting held on January 07, 2025, has approved the allotment of 4,000 equity shares of the face value of Re. 1/-each to the eligible employee who have exercised their stock options under Bliss GVS Pharma Limited-Employee Stock Option Plan ("Bliss GVS ESOP-2019").'. | Download
Bliss GVS Pharma Limited has informed the Exchange regarding 'We like to inform you that, the ESOP Allotment Committee of the Company at its meeting held on January 07, 2025, has approved the allotment of 4,000 equity shares of the face value of Re. 1/-each to the eligible employee who have exercised their stock options under Bliss GVS Pharma Limited-Employee Stock Option Plan ("Bliss GVS ESOP-2019").'. | Download
Final • Div/Share: ₹ 0.5
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant